Combination ACEI and ARB therapy: additional benefit in renoprotection?

Area of Science:

• Nephrology
• Pharmacology
• Cardiovascular Medicine

Background:

• Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are established treatments for chronic kidney disease (CKD).
• These drugs target the renin-angiotensin system (RAS) at different points, suggesting potential additive effects.
• There is an ongoing need for more effective renoprotective strategies to slow CKD progression.

Purpose of the Study:

• To review experimental and clinical evidence on the combined use of ACEIs and ARBs for renoprotection.
• To evaluate the hypothesis that combination therapy provides additive renoprotective benefits beyond monotherapy.

Main Methods:

• Review of existing experimental studies investigating the effects of combined ACEI and ARB therapy.
• Analysis of clinical trial data, including studies on diabetic nephropathy and non-diabetic CKD.
• Assessment of antihypertensive and antiproteinuric effects of combination therapy versus monotherapy.

Main Results:

• Experimental studies have not definitively separated additive antihypertensive effects from intrinsic renoprotective effects.
• Clinical studies, despite small sample sizes and short durations, indicate greater antihypertensive and antiproteinuric responses with combination therapy.
• Combination therapy demonstrated superior outcomes in both diabetic nephropathy and non-diabetic CKD compared to monotherapy.

Conclusions:

• Addition of ARBs is recommended for patients with persistent hypertension or proteinuria while on ACEI therapy.
• Further long-term studies are necessary to fully ascertain the renoprotective potential and safety of combined ACEI and ARB use.
• This combination strategy holds promise for improving renoprotection in chronic renal disease management.